Apexigen Inc
Change company Symbol lookup
Select an option...
APGN Apexigen Inc
MSFT Microsoft Corp
SDA SunCar Technology Group Inc
SLNH Soluna Holdings Inc
TPST Tempest Therapeutics Inc
PETV PetVivo Holdings Inc
KMI Kinder Morgan Inc
NXPL NextPlat Corp
D Dominion Energy Inc
CVS CVS Health Corp
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Apexigen, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient’s immune system to combat and eradicate cancer. It has developed a clinical-stage candidate, namely sotigalimab (sotiga or APX005M), which is a humanized agonist antibody. It also has various preclinical and research-stage antibodies it discovered using its APXiMAB platform. It is focused on completing ongoing clinical and manufacturing activities for the sotiga program. The Company’s licensees are advancing five product candidates in clinical development that were enabled by discoveries from its APXiMAB platform. APX005M is under Phase II clinical development for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction cancers and melanoma, in combination with chemotherapy, radiation therapy and immunotherapy.

Closing Price: $0.54

Day's Change: 0.042 (8.43%)

Bid: --

Ask: --

B/A Size: --

Day's High: 0.5802

Day's Low: 0.4713

Volume (Light) Volume: 904,162 10-day average volume: 1,183,003: 904,162

May 25, 2023
12:25 pm ET	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXDX, RUTH, APGN, CWBR NEW YORK, NY / ACCESSWIRE / May 25, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating...(Accesswire)
11:51 am ET	Moore Kuehn Encourages CWBR, RXDX, RUTH, and APGN Investors to Contact Law Firm(Globe Newswire)
10:00 am ET	SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Apexigen, Inc. Buyout Wilmington, Delaware--(Newsfile Corp. - May 25, 2023) - Rigrodsky Law, P.A. is investigating Apexigen, Inc. ("Apexigen") (NASDAQ: APGN) regarding possible breaches of fiduciary duties and other violations of law related to Apexigen's agreement to be...(Newsfile)
May 24, 2023
12:37 pm ET	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNL, RTL, APGN Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: (PR Newswire)
10:34 am ET	Shareholder Alert: Ademi LLP investigates whether Apexigen, Inc. has obtained a Fair Price in its transaction with Pyxis Oncology Ademi LLP is investigating Apexigen (Nasdaq: APGN) for possible breaches of fiduciary duty and other violations of law in its transaction with Pyxis Oncology. https://mma.prnewswire.com/media/1580107/Ademi_LLP_Logo.jpg (PR Newswire)
8:16 am ET	APGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Apexigen, Inc. Is Fair to Shareholders Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Apexigen, Inc. (NASDAQ: APGN) to Pyxis Oncology, Inc. for 0.1725 shares of Pyxis for each share of Apexigen is fair to Apexigen shareholders. Upon closing of the...(BusinessWire)
6:45 am ET	Pyxis Oncology to Acquire Apexigen(Globe Newswire)
February 27, 2023
8:00 am ET	Apexigen Announces Review of Strategic Alternatives and Restructuring(Globe Newswire)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and